ClinicalTrials.gg
Active, not recruitingNCT03989414Updated Nov 29, 2024

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

A Phase 1/2 interventional study of CC-92480 and Bortezomib in Multiple Myeloma, sponsored by Celgene. Active, not recruiting at 49 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
424
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 149 studies in Multiple Myeloma by Bristol-Myers Squibb — 9 open to participants now, 18 under way, 6 of them phase 3. Multiple Myeloma · Bristol-Myers Squibb.

Planned enrollment
18th of 108
424 · median 83
Started
2019
with 2 others
Phase 1/2
12 of 149
2 open now
Primary completion
2026-11
later than 5 of 17 live
Registered
120th of 149
by date

Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 18th largest by planned enrollment of the 108 interventional ones that give a count, is one of 3 that started in 2019, is one of 12 in phase 1/2, reaches primary completion later than 5 of the 17 other live ones, and was the 120th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

9 of the 149 studies in Multiple Myeloma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Multiple Myeloma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Relapsed or Refractory Multiple Myeloma
  • Newly Diagnosed Multiple Myeloma
  • Multiple Myeloma
  • CC-92480
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status score of 0, 1 or 2

For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:

  • Documented diagnosis of multiple myeloma (MM) and
  • Documented disease progression during or after their last antimyeloma regimen
  • Achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen

Exclusion criteria

Exclusion Criteria:

  • Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or amyloidosis
  • Known central nervous system (CNS) involvement with myeloma
  • Received medication within the last 14 days of initiating study treatment
  • Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
424 participants (estimated)

Study arms

  • Experimental
    Cohort A: CC-92480 with bortezomib and dexamethasone

    Drug: CC-92480 · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Cohort C: CC-92480 with carfilzomib and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Carfilzomib

  • Experimental
    Cohort H: CC-92480 with elotuzumab and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Elotuzumab

  • Experimental
    Cohort I: CC-92480 with isatuximab and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Isatuximab

  • Experimental
    Cohort D: CC-92480 with bortezomib and dexamethasone

    Drug: CC-92480 · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Cohort F: CC-92480 with carfilzomib and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Carfilzomib

  • Experimental
    Cohort J: CC-92480 with elotuzumab and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Elotuzumab

  • Experimental
    Cohort K: CC-92480 with isatuximab and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Isatuximab

  • Experimental
    Cohort G: CC-92480 with bortezomib and dexamethasone

    Drug: CC-92480 · Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Subcohort B1: CC-92480 with daratumumab and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Daratumumab

  • Experimental
    Subcohort B2: CC-92480 with daratumumab and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Daratumumab

  • Experimental
    Subcohort B3: CC-92480 with daratumumab and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Daratumumab

  • Experimental
    Subcohort E1: CC-92480 with daratumumab and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Daratumumab

  • Experimental
    Subcohort E2: CC-92480 with daratumumab and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Daratumumab

  • Experimental
    Subcohort E3: CC-92480 with daratumumab and dexamethasone

    Drug: CC-92480 · Drug: Dexamethasone · Drug: Daratumumab

Interventions

06

What researchers measure

Primary outcomes

  1. Recommended Dose

    Time frame: Up to approximately 3 years

  2. Recommended regimen as measured by dose-limiting toxicities

    Time frame: Up to approximately 3 years

  3. Number of participants with Adverse Events (AEs)

    Time frame: From first participant first visit until 28 days after the last subject discontinues study treatment, up to 5 years

  4. Overall response rate (ORR)

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Time-to-response (TTR)

    Time frame: Up to approximately 5 years

  2. Duration of response (DOR)

    Time frame: Up to approximately 5 years

  3. Complete Response (CR) rate

    Time frame: Up to approximately 5 years

  4. Very good partial response (VGPR) rate - Cohorts D and E

    Time frame: Up to approximately 5 years

07

Study locations

49 sites
  • Local Institution - 119
    Denver, Colorado 80218, United States
  • Local Institution - 104
    Tampa, Florida 33612, United States
  • Local Institution - 108
    Atlanta, Georgia 30322, United States
  • Local Institution - 112
    Chicago, Illinois 60611, United States
  • Local Institution - 107
    Chicago, Illinois 60637, United States
  • Local Institution - 117
    Boston, Massachusetts 02114, United States
  • Local Institution - 101
    Boston, Massachusetts 02115, United States
  • Local Institution - 118
    Boston, Massachusetts 02215, United States
  • Local Institution - 113
    Detroit, Michigan 48201, United States
  • Local Institution - 106
    Rochester, Minnesota 55905, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Local Institution - 110
    Winston-Salem, North Carolina 27157, United States
  • Local Institution - 115
    Columbus, Ohio 43210, United States
  • Local Institution - 114
    Nashville, Tennessee 37203, United States
  • Local Institution - 116
    Houston, Texas 77030, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Local Institution - 201
    Calgary, Alberta T2N 4N2, Canada
  • Local Institution - 205
    Edmonton, Alberta T6G 2G3, Canada
  • Local Institution - 204
    Halifax, Nova Scotia B3H 1V7, Canada
  • Local Institution - 203
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 202
    Montreal, Quebec H1T 2M4, Canada
  • Local Institution - 802
    Brno, 625 00, Czechia
  • Local Institution - 801
    Ostrava-Poruba, 708 52, Czechia
  • Local Institution - 803
    Praha 2, 128 08, Czechia
  • Local Institution - 902
    Odense, 5000, Denmark
  • Local Institution - 903
    Vejle, 7100, Denmark
  • Local Institution - 703
    Lille cedex, 59037, France
  • Local Institution - 705
    Marseille cedex, 13273, France
  • Local Institution - 704
    Nantes Cedex 01, 44093, France
  • Local Institution - 701
    Toulouse Cedex 9, 31059, France
  • Local Institution - 702
    Tours cedex, 37044, France
  • Local Institution - 604
    Freiburg, 79106, Germany
  • Local Institution - 605
    Hamburg, 20246, Germany
  • Local Institution - 601
    Heidelberg, 69120, Germany
  • Local Institution - 602
    Munchen, 81675, Germany
  • Local Institution - 603
    Wuerzburg, 97080, Germany
  • Local Institution - 301
    Athens, 115 28, Greece
  • Local Institution - 404
    Brescia, 25123, Italy
  • Local Institution - 401
    Milan, 20133, Italy
  • Local Institution - 403
    Reggio Emilia, 42100, Italy
  • Local Institution - 402
    Torino, 10126, Italy
  • Local Institution - 504
    Badalona, 08916, Spain
  • Local Institution - 508
    Madrid, 28022, Spain
  • Local Institution - 501
    Madrid, 28041, Spain
  • Local Institution - 506
    Malaga, 29010, Spain
  • Local Institution - 505
    Pamplona, 31008, Spain
  • Local Institution - 502
    Salamanca, 37007, Spain
  • Local Institution - 503
    Santander, 39008, Spain
  • Local Institution - 507
    Valencia, 46026, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Nov 2026, 86 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 86 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2019
First posted
Jun 18, 2019
StartActual
Sep 30, 2019
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03989414
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jun 18, 2019
Start date
Sep 30, 2019
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 29, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion